Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Phase 3

Completed

• Conditions: Mixed Hyperlipidemia; Non-familial Hypercholesterolemia
• Interventions: Drug: SHR-1209 ;placebo

• Registration Number: NCT04885218
• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Brief Summary

To evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SHR-1209 subcutaneous administration in patients with non-familial hypercholesterolemia and mixed hyperlipidemia after lipid-lowering therapy

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-30
• Study First Submitted QC: 2021-05-07
• Study First Posted: 2021-05-13
• Study Start: 2021-07-30
• Primary Completion: 2023-05-23
• Study Completion: 2023-05-23
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-29
• Last Update Posted: 2024-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 692

Inclusion Criteria

1. Age ≥18 and ≤80 on the date of signing the informed consent, male or female;
2. The report of LDL-C should be higher than the ideal lipid-lowering target according to ASCVD history;
3. Fasting triglycerides less than equal to 5.6 mmol/L；
4. Understand the study procedures and methods, volunteer to participate in the study, and sign the informed consent.

Exclusion Criteria

1. Have the following diseases or treatment history : (1) Have known allergic reaction to experimental drugs, or have severe allergic reaction to other antibody drugs;(2) previous diagnosis of familial hypercholesterolemia according to Simon Broome Criteria;(3) cardiac function as defined by the New York Heart Association (NYHA) grade III-IV at screening or randomization or latest detected LVEF<30%;(4) CVD events within 3 months; (5) uncontrolled hypertension; (6) prior exposure to recaticimab or other PCSK9 inhibitors; (7) inadequate organ functions.
2. Any of the laboratory indicators met the following criteria at screening or at randomization :(1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 3 times the upper limit of normal (ULN), or total bilirubin exceeding 2 times the upper limit of normal (ULN);(2) Creatine kinase (CK) exceeds 3 times the upper limit of normal value (ULN);
3. General conditions :(1) the investigator judged that subcutaneous injection was not appropriate;(2) Fertile female subjects who did not use contraception within 4 weeks before screening; Or male or female subjects who do not agree to use high-efficiency contraceptives during the trial and for 24 weeks after the last dosing;(3) Women who are pregnant or lactating.
4. The Investigator determines that the subjects have poor compliance or have any factors that may prevent them from participating in the study, including, but not limited to, the study placing the subjects at unacceptable risk or possibly interfering with the study results.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 2：SHR-1209 /placebo	SHR-1209 ;placebo	-
Cohort 1：SHR-1209 / placebo	SHR-1209 ;placebo	-
Cohort 3：SHR-1209 / placebo	SHR-1209 ;placebo	-

Primary Outcome Measures

Name	Time	Method
Percentage change in LDL-C relative to baseline	at 24 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
Percentage change in TC/HDL-C relative to baseline,	at 48 weeks of treatment
Percentage change in LDL-C relative to baseline	at 48 weeks of treatment;
Percentage change in LP (a) relative to baseline,	at 48 weeks of treatment;
Percentage change in non-HDL-C relative to baseline	at 48 weeks of treatment;
Percentage change in TC/HDL-C relative to baseline	at 24 weeks of treatment;
The value of change in LDL-C relative to baseline ,	at 48 weeks of treatment;
Percentage change in ApoB relative to baseline	at 48 weeks of treatment;
Percentage change in ApoB/ApoA1 relative to baseline,	at 48 weeks of treatment;
Percentage of patients who achieved LDL-C goal according to presence of ASCVD at baseline,	at 48 weeks of treatment.
The value of change in LDL-C relative to baseline	at 24 weeks of treatment
Percentage change in TG relative to baseline	at 48 weeks of treatment;

Trial Locations

Locations (1)

Beijing Anzhen hospital; 🇨🇳 Beijing, Beijing, China